« Previous
Next »
Titles
- A sense of déjà vu: the debate surrounding state biosimilar substitution laws1
- Administrative rulemaking1
- Alternative pricing models for remdesivir and other potential treatments for COVID-191
- Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents1
- Bending the curve: options for achieving savings and improving value in U.S. health spending1
- Biologics in perspective: the case for generic biologic drugs1
- Business of healthcare1
- CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments1
- Calculation of potential inflation-indexed rebates for Medicare Part B drugs1
- CardioMEMS (tm) HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto (tm), Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks : final report1
- Closing the "doughnut hole" has helped protect millions of Medicare beneficiaries from high drug costs1
- Competitive bidding in drug procurement: evidence from China1
- Coverage and payment for prescription drugs under Medicare Part B: a complex patchwork1
- Does Medicare Part D protect the elderly from financial risk?1
- Drug discount program: federal oversight of compliance at 340B contract pharmacies needs improvement : report to Congressional requesters1
- Drug discount program: improvements needed in federal oversight of compliance at 340B contract pharmacies : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives1
- Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate1
- Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters1
- Drug price increases that exceed inflation are costing Medicare Part D billions1
- Drug price moderation in Germany: lessons for U.S. reform efforts1